Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

• Published in: Journal of Cancer Vol. 15; no. 7; pp. 2024 - 2032
• Main Authors: Cao, Qiang, Zhu, Jinyi, Wu, Xinyan, Li, Jiapeng, Chen, Yuquan, You, Yanwei, Li, Xiaochen, Huang, Xufeng, Zhang, Yujie, Li, Rizhu, Han, Dan
• Format: Journal Article
• Language: English
• Published: Australia 2024
• Subjects: Advanced Non-Small Cell Lung Cancer; Interleukin-2 Treatment; Intrathoracic Perfusion Chemotherapy; Efficacy and Safety Evaluation; Retrospective Cohort Study; immunotherapy
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/jca.92624

This study evaluated the efficacy and safety of the gemcitabine and oxaliplatin intrathoracic perfusion chemotherapy (IPCGOR) regimen combined with interleukin-2 (IL-2) for advanced non-small cell lung cancer (NSCLC).
We conducted a retrospective analysis of 460 advanced NSCLC patients from the Yunnan Province Early Cancer Diagnosis and Treatment Project (June 2020-October 2022), assessing the IPCGOR and IL-2 combination. Outcomes were measured based on RECIST 1.1 criteria, focusing on objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (MOS), and treatment safety.
The treatment demonstrated an ORR of 67.4%, a DCR of 97.4%, an mPFS of 8.5 months, and an MOS of 12.5 months. 14 patients underwent successful surgery post-treatment. Common adverse reactions were manageable, with no treatment-related deaths reported.
The IPCGOR combined with IL-2 regimen shows promising efficacy and a tolerable safety profile for advanced NSCLC. These findings suggest its potential as a reference for treating advanced NSCLC. However, the study's retrospective nature and single-center design pose limitations. Future research should focus on prospective studies, randomized controlled trials, and long-term outcome assessments, particularly in diverse patient subgroups, to further validate and refine the clinical application of this regimen.